Moderna, Inc. (M1RN34.SA)
| Previous close | 38.01 |
| Open | 38.12 |
| Bid | 35.90 x N/A |
| Ask | 41.50 x N/A |
| Day's range | 36.93 - 41.31 |
| 52-week range | 16.70 - 44.00 |
| Volume | |
| Avg. volume | 19,121 |
| Market cap | 287.43B |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.06 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaModerna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna, the first being the famed COVID-19 vaccine. Earlier this month, the FDA, citing administrative constraints, delayed the review of the vaccine’s applicat
AFPUS approves Moderna's RSV vaccine for older adults
The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- marking the first time any mRNA shot has been authorized against a disease other than Covid-19.A global study of approximately 37,000 people aged 60 and older found the shot had an efficacy of 83.7 percent against lower respiratory tract disease -- meaning when an RSV becomes more severe and can cause pneumonia, bronchitis, shortness of breath and more.
Investor's Business DailyModerna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
